Summary: Regional cerebral muscarinic cholinergic re ceptor binding was quantified in normal young and elder ly subjects employing the muscarinic antagonist radioli gand [IlCltropanyl benzilate (TRB) . Binding was deter mined by kinetic analyses of positron emission tomographic (PET) determinations of cerebral activity in conjunction with radial arterial blood sampling following intravenous radio tracer injection. A significant, but minor (8%), loss of frontal cortical receptors relative to whole brain average receptor density was found with advancing age. Parametric estimates of binding suggest small reduc tions in cerebral cortex binding as well as increases in Central nervous system cholinergic function is believed to play an important role in memory and cognition (Longo, 1966; Drachman, 1977; Bartus et aI., 1982; Sunderland et aI., 1987; Molchan et aI., 1992) . Impaired presynaptic cholinergic activity is associated with cognitive impairment in Alzhei mer's disease (Coyle et aI., 1983; Whitehouse et aI., 1988a) Parkinson's disease (Dubois et aI., 1987; Whitehouse et aI., 1988a) , Down's syndrome (Yates et aI., 1980) , and progressive supranuclear brain stem and cerebellar binding underlying the ob served pattern difference. However, these latter changes did not achieve statistical significance. We conclude that cerebral muscarinic receptor availability, as depicted by antagonist binding, does not undergo a major decline dur ing normal aging of the adult human brain. The cerebral cortical cholinergic dysfunction in elderly subjects, sug gested by prior clinical evidence, is not attributable to major loss of total muscarinic cholinoceptive capac ity. Key Words: Muscarinic receptor-Human brain Positron emission tomography-Aging-Tropanyl benzi late.
palsy (Whitehouse et aI., 1988b) . These findings have led to rational therapeutic trials of direct mus carinic agonist and indirect cholinergic agonist treatments of Alzheimer's disease (Agnoli et aI., 1983; Eagger et aI., 1991) and progressive supranu clear palsy (Foster et aI., 1989 ). The potential for success of these therapeutic approaches is, how ever, dependent on intact muscarinic cholinergic re ceptors.
Postmortem assays have revealed conflicting re sults regarding the integrity of muscarinic cholin ergic receptors in these diseases as well as in nor mal aging (Whitehouse and Au, 1986; Gottfries, 1990) . Studies of normal human brain have indi cated either decreased (White et aI., 1977; Rinne, 1987; Perry, 1980) or unchanged (Davies and Verth, 1977; Allen et aI., 1983 ) muscarinic receptor bind ing. These discrepancies may be attributed to sources of variation, e.g., preterminal illness and nutrition, drug effects (Whitehouse and Au, 1986; Freund and Ballinger, 1989) , postmortem delay to tissue procurement, and tissue storage prior to as-say (Whitehouse et aI., 1984; Cortes et aI., 1987; Zilles et aI., 1988) .
Clarification of expressed levels of muscarinic cholinergic receptors in the course of normal aging is essential to the evaluation of the role of cholin ergic neurotransmission and its alteration in age associated conditions, including Alzheimer's dis ease, and may ultimately assist in the development of new therapies for cognitive disorders (White house and Au, 1986) . In the present study, we quan titatively mapped the distribution of cerebral mus carinic receptors in vivo in neurologically normal young adult and elderly subjects with use of posi tron emission tomography (PET) and the antagonist radioligand [llC]tropanyl benzilate (TRB). Previ ously, we evaluated the tracer kinetic behavior of TRB in relation to estimation of muscarinic cholin ergic receptors, our results indicating the feasibility of detecting normal or disease-related changes in human brain (Koeppe et aI., 1994) .
METHODS

Subjects
All studies were given prior approval by the University of Michigan Institutional Review Board and by the Sub committee on Human Use of Radionuclides. Addition ally, the use of [IIC]TRB was under the auspices of an investigational new drug application, approved by the U.S. Food and Drug Administration. Written informed consent was obtained from all subjects prior to initiation of experimental procedures.
Six young (aged 24 ± 3 years, range, 20-28 years; four men and two women) and eight elderly (aged 67 ± 8 years, range, 55-76 years; five men and three women) normal subjects were studied. All subjects were free of neurologic, psychiatric, or serious medical illnesses on medical history, general physical, and neurologic exami nations. Normal neuropsychometric testing results in the elderly group excluded the possibility of subclinical cog nitive impairment. Evaluations performed included the Wechsler Adult Intelligence Scale-Revised (Wechsler, 1981) , the Wide Range Achievement Test-Revised (Jas tak, 1965), the Mini Mental State Examination (Folstein et aI., 1975) , the Boston Naming Test (Kaplan et aI., 1978) , Verbal Fluency (Lezak, 1983) , the Wechsler Memory Scale-Russell Modification (Russell, 1975) , the Rey Osterreith Complex Figure Test (Kimura, 1984) , and the Self-Rating (Berent et aI., 1982) . All subjects were free of any centrally-acting medications for a minimum period of 1 month prior to study. All were nonsmokers and all de nied history of recreational drug use or excessive con sumption of alcohol or caffeine.
Collection of brain and arterial tracer curves e lClTRB was synthesized as previously described (Mulholland et aI., 1992) graph (CTI Inc., Knoxville, TN, U.S.A), which simulta neously images 15 slices each separated by 6.75 mm (Spinks et aI., 1988) . Subjects were positioned supine on the scanner bed in a dimly-lit room with eyes and ears unoccluded. Antecubital vein and radial arterial cannulae were placed for injection of tracer and withdrawal of blood samples, respectively. Four-to-five fiduciary beads, labeled with "C, were affixed to the forehead and retroauricular scalp regions of each subject at the begin ning of each study. Data acquisition commenced with bolus intravenous administration of 25-50 mCi of [IIC]TRB containing < 10 f,Lg tracer mass. Dynamic imaging over a 110 min interval was performed as follows: 2 x 30 sa nd 4 x 1, 2 x 2.5, 2
x 5, 7 x 10, and 1 x 20 min. Image data were recon structed to an in-plane and axial spatial resolution of �8 mm full width at half maximum, using ellipse-calculated attenuation correction factors. Images were corrected for decay and acquisition time and then for subject motion during the image acquisition sequence. Motion correction was accomplished by noting the spatial positions of the fiduciary beads in the reference frame (50-60 min frame). Other frames in the dynamic imaging sequence were then realigned to this frame on the fiduciaries, resulting in re alignments to within 0.5 mm (translational) and 10 (rota tional), as determined from phantom studies (Koeppe, RA unpublished observations). These procedures re sulted in a series of spatially-registered images depicting [IIC]TRB concentration within each scanned volume el ement.
Arterial plasma samples were obtained every 10 s for the first 2 min and then at 2. 5, 3, 4, 5, 7.5, 10, 15, 20, 30, 45, 60, 90 , and 110 min postinjection of [IIC]TRB. Plasma samples obtained at 1, 2, and �3 min postinjection inter vals were corrected for the presence of labeled metabo lites using liquid chromatography, as previously de scribed (Frey et aI., 1992; Koeppe et aI., 1994) ."C activ ities in total plasma samples and in chromatographic assays were determined in a sodium iodide well counter that was cross-calibrated to tomograph sensitivity.
Estimation of muscarinic receptor binding
Single, anatomically-configured midline regions of in terest (ROIs) were drawn on the 50-60 min frame corre sponding to the occipital (primary visual) cortex and pons. Bilateral ROIs were placed corresponding to the dorsal frontal (motor and premotor) and parietal (hetero modal association) cortices, cerebellum, caudate, puta men, and thalamus. In addition, whole brain activity was estimated from the area-weighted average of ROIs corre sponding to the entire brain at each transaxial leveI. ROI templates were saved and subsequently applied to the entire temporal sequence of activity images (for kinetic analyses) and to pixel-by-pixel parametric images (see be low).
Two previously-described methods were employed for determination of TRB binding to muscarinic receptors. The first was a pixel-by-pixel weighted integral estimation (Alpert et aI., 1984) of TRB transport (K I ) and binding [tissue distribution volume (DV)], calculated according to a two-parameter, two-compartment analysis of the cere bral and arterial tracer activity curves (Koeppe et aI., 1994) . This method provides images of both ligand deliv ery and binding; however, there is a systematic underes-timation of binding, DV, in regions of highest receptor density. The second was a constrained, four-parameter, three-compartment kinetic analysis , which allows, more accurate but less precise binding es timates. The model in this instance includes parameters representing bidirectional exchange of tracer between blood and brain (Kj and k2'), receptor binding (k3" equiv alent to the kon x Bmax product in in vitro assays) and dissociation (k4, equivalent to koff)' Simultaneous estima tion of the four-rate parameters was performed in the cerebellar ROI; however, this was not routinely feasible in regions of higher receptor binding due to difficulty in estimating k2' and k4 in the presence of very rapid specific binding (high k3')' Therefore, it was assumed that the nonspecific and free ligand distribution volumes (speci fied by the K/k2' ratio) and the ligand dissociation rate from specific binding sites (k4) are identical across the examined gray matter ROls. Thus, k4 was constrained to the popUlation mean of all subjects' cerebellar values, and the Kj/k2' ratio was constrained to the value obtained from analysis of each subject's own cerebellar ROls. Nonlinear least-squares curve fitting was then applied to the ROI activity curve sequences for estimation of Kj and k3"
Data analyses and statistics
Transport and binding data were averaged for the bi hemispheric regions, providing a single estimate for each region per subject. Data from the pixel-by-pixel analyses were examined both in parametric values as well as ex pressed values relative to individual brain average, em phasizing more subtle pattern distinctions. Differences between groups were assessed with repeated measures analysis of variance (MANOVA), employing brain region as the repeated measure, at a significance threshold of p < 0.05. For instances in which significant between-group or group-by-region interaction effects were indicated, posthoc two-tailed Student's t-tests were conducted. No formal correction for mUltiple parallel comparisons was employed; however, results of posthoc analyses were considered significant only at the p < 0.01 level. Addi tionally, linear regression analyses of cerebellar and fron tal cerebral cortical binding estimates were conducted to investigate the possibility that between-group differences might be masked by age ranges within the study groups.
RESULTS
Two-compartment kinetic analyses
Parametric K ) and DV estimates did not differ between the young and elderly groups (Table 1) (F = 2.67, p = 0. 15, and F = 2.42, p = 0. 17, in analyses of region-by-group interactions in MANOVA of K) and DV data, respectively). When data were expressed relative to whole brain aver ages, K) was again comparable between the groups (F = 1.99, p = 0. 2 1). Analysis of DV, however, indicated the possibility of an alteration in the pat tern of muscarinic receptor binding (F = 5. 14, p = 0.032). Subsequent regional analyses indicated a trend toward relatively increased binding in poste rior fossa structures and decreased binding in fron tal and occipital cortices with advancing age; only the reduction in the frontal cortex achieved statis tical significance. Comparison of these data with untransformed parametric values suggested the presence of both neocortical and posterior fossa trends. However, the magnitude of the frontal cor tex decline was only 12% (p = 0. 105, not signifi cant) in parametric estimates and 8% (p < 0.00 1) in binding expressed relative to the global mean.
Three-compartment kinetic analyses
Since the constrained three compartment binding estimates depend, in part, on the values assigned to the fixed parameters, potential intergroup differ ences in both the binding dissociation rate and in the distribution volume of nonspecific and free ligand were investigated in the cerebellum. There was no significant difference in the dissociation rate of specific TRB binding between groups (k4 esti mates of 0. 04 ± 0.03 min -) and 0. 03 ± 0.01 min -) in young and elderly subjects, respectively; p = 0.29). The mean value of all subjects, 0. 032 min -) , was employed in all subsequent fitting analyses. Cerebellar distribution volumes for free and non specific TRB (K/k2' ratio, estimated with k4 fixed to 0.032 min -I) were 2.5 ± 0.4 mllg in young and 2.3 ± 1.3 mllg in elderly subjects (p = 0.69).
Estimates of muscarinic receptor binding in re ceptor-rich regions from the constrained three compartment and from the two-compartment pixel by-pixel analyses were in good agreement; how ever, the more complex model estimates demonstrated greater variability ( Fig. 1) (K oeppe et aI., 1994) . No significant differences were seen in TRB binding estimates (MANOV A revealed no sig nificant k3' region by group interaction; F = 2.70, p = 0.12).
Linear regression analyses
The possibility that within-group variance due to age ranges might have masked detection of signifi cant effect was investigated in the frontal cortex and cerebellum by linear regression analyses. In the frontal cortex (Fig. 2) , declines of 0. 19, 0. 14, and 0.10%/year were indicated by DV, normalized DV, and k3' binding estimates, respectively. Only the normalized DV data demonstrated a statistically significant age relationship. Cerebellar binding anal yses (Fig. 3) suggested increases ofO.96/(DV), 0.821 (normalized DV), and 0.84%/yr (k3'), none of which achieved statistical significance.
DISCUSSION
The primary finding in the present study is a lack of substantial change in the binding of the antago nist ligand [IIC]TRB during normal aging in the adult human brain. Our current methods depict binding at a single, sub saturating ligand dose, per mitting estimations only of the forward binding rate J Cereb Blood Flow Metab, Vol. 16, No. 2, 1996 (proportional to Bmax x kon) or of the total tissue DV (proportional to Bmax x kd' but with an added component attributable to nonspecific binding and free ligand in tissue). There are numerous in vitro studies of aging effect on muscarinic receptors in rodent and primate brain (see below) that collec tively indicate unchanged antagonist binding affin ity (kd) , but suggest apparently discrepant results regarding receptor density (Bmax). Thus, we inter pret our findings and review the prior literature with the assumption that age-related antagonist binding changes reflect differences in receptor density. Ap parent lack of agreement on the presence and mag nitude of age-related changes in prior in vitro stud ies is resolved by considering the distinction be tween developmental changes that occur in advance of adulthood versus aging of the adult brain.
In vitro radioligand binding studies of mouse brain have indicated loss of receptors in the interval between the ages of 4 and 30 months (Freund, 1980; Waller and London, 1983) . It has been further re ported that aging effects are regional; there are � 30% loss of striatal and 60% loss of neocortical muscarinic receptors, with unchanged or elevated receptor numbers in the cerebellum and hippocam pal formation (Waller and London, 1983) .
In the rat, atropine binding to synaptosomal frac tions reveals an age-associated 50% decline in the Each point represents the mean ± SEM for a specific brain region (cerebellar cortex, pons, thalamus, parietal cortex, frontal cortex, occipital cortex, caudate, and putamen in as cending order for elderly subjects) in a group (young, 0, elderly, e). Using a quadratic regression model, the correla tion between measures for these points was r = 0.99, P < 0.0001. [11C]TRB binding versus age. Three methods for estimation of TRB binding to muscarinic cholinergic receptors are de picted: the DV from a pixel-by-pixel analysis of a two compartment model (e); DV expressed relative to whole brain average (DV norm ' "'); and the rate of receptor binding (k3" _) derived from regional kinetic analyses with a con strained, three-compartment kinetic model. All three meth ods suggest minor declines in binding with advancing age, however, statistical significance is demonstrated only for normalized D V data. Equations of the regression lines are: DV = 26.011 -0.050 x age (r = 0.31, P = 0.29); DV norm = 1.452 -0.002 x age (r = 0.71, P = 0.005); and k3 = 0.548 -0.00053 x age (r = 0.081, P = 0.78).
cerebral cortex between ages 2 and 20 months, while cerebellar binding increases between 2 and 10 months and then declines to initial levels (James and Kanungo, 1976) . Conversely, subsequent stud ies of Morin and Wasterlain (1980) failed to detect changes in total muscarinic receptor binding in the cerebral cortex, hippocampus, amygdala, or hypo thalamus between the ages of 4 and 22 months. A significant striatal receptor decline of 30% and an insignificant trend toward receptor loss in the cer ebellum (25% reduction) were observed. A subse quent study revealed modest (-20-25%) declines in cerebral cortical, hippocampal, and striatal musca rinic receptors, with a 60% increase in the brain stem of male, but not female, brains between the ages of 3-4 and 27-30 months (Gurwitz et al., 1987) .
A more recent study that addressed aging effects on muscarinic receptors employed autoradiography of intact brain sections and detected minor changes in cerebral cortical (-15% decreases) and unaltered hippocampal binding between the ages of 4 and 31 months (Biegon et al., 1988) . Striatal changes were limited to an apparent 17% loss of receptors from the dorsomedial caudate putamen, while pontine and cerebellar binding were reduced by -30%. Thus, changes observed in several laboratories are in general agreement that minor reductions in cere bral cortical and striatal muscarinic receptor ex pression are observed in the aging adult rodent brain. Studies indicating larger decreases have in cluded adolescent subjects for initial reference, sug gesting that developmental, rather than senescence related, changes predominate. Binding results in Macaca mulatta are in agreement with rodent data. Wenk et al. (1989) found no signif icant decline in muscarinic M I-type receptors in the frontopolar cerebral cortex of monkeys between the ages of 4 and 31 years. Wagster et al. (1990) reported reduction in total muscarinic binding in the temporal neocortex that is greatest between the ages of 2 and 6 years (15% decline) and least between 13 and 20 years (8% decline) of age. Subcortical regions were not as sayed in these studies.
Postmortem examinations of human brain have yielded less consistent results than have the afore mentioned nonhuman studies. Most investigations have been restricted to middle-aged and elderly adult subjects, and included individuals with a va riety of preterminal illnesses and drug exposures. Several studies have suggested modest declines in cerebral cortical or hippocampal muscarinic recep tors between the ages of 60 and 90 years (White et aI., 1977; Perry, 1980; Nordberg and Winblad, 198 1) . Others, however, have not identified such changes (Davies and Verth, 1977; Allen et aI., 1983) . The series with the greatest age ranges and subject numbers (Rinne, 1987) indicates �50% re ductions in muscarinic receptor numbers in the stri atum, hippocampus, and frontal cortex between ages 4 and 93 years. Although the highest receptor densities were found in the eight subjects :;;; ; 20 years of age, age-associated declines of lesser magnitude were evident in the data from the adult subjects as well.
Recognizing the limitations inherent in human au topsy studies, two prior investigations employed in vivo neuroimaging techniques to estimate cerebral muscarinic receptor populations in human aging. The first study (Dewey et aI., 1990) utilized the an tagonist radioligand [llC]benztropine. Seven sub jects between the ages of 19 and 82 years of age were evaluated employing arterial plasma tracer sampling with metabolite correction and dynamic PET imaging. Age-related reductions in tracer con centration were observed in all cerebral regions re ported. Additional analyses of the total tissue dis tribution volumes of benztropine, expressed rela tive to the cerebellum, suggested a decline of 50% in all of the neocortical regions and in the striatum. No change was suggested in the thalamus. The second investigation of muscarinic receptor changes in ag ing human brain with PET (Suhara et aI., 1993) made use of the more recently developed antagonist ligand [llC]N-methylpiperidyl benzilate (NMPB) (Mulholland et aI., 1994) and analyzed the dynamic time-course of cerebral tracer activity, expressed in comparison with cerebellar activity as an assumed nonspecific and free tracer reference region. This analysis revealed apparent 45% decreases in bind ing in all neocortical regions, hippocampus, stria tum, thalamus, and pons between ages 18 and 75 years.
In contrast to the prior PET studies, our present findings are in agreement with the majority of the cited in vitro and postmortem studies and do not confirm the presence of large, age-related reduc tions in cerebral muscarinic receptors. Rather, we observed minor, insignificant trends toward re duced frontal (12% decline) and occipital (17% de cline) cortical and toward elevated cerebellar (25% increase) muscarinic binding as estimated by the untransformed DV of [llC]TRB. Directions and magnitudes of these trends were similar despite the application of two distinct analytic schemes, each J Cereb Blood Flow Metab, Vol. 16, No.2, 1996 with distinct relative strengths and biases (Koeppe et aI., 1994) . The combination of opposing cortical and posterior fossa changes may have led prior PET investigators, employing the cerebellum as a refer ence region, to conclude that the loss of cerebral muscarinic receptors was more substantial than that reported here. In fact, the ratios of our mean frontal to cerebellar TRB binding estimates would lead to estimated cortical reductions of 26-37% for the var ious analysis schemes, attributable largely to the cerebellar increase. Power analyses indicate that we have 92 and 73% probabilities of having identi fied 50% losses in cortical receptors in the present untransformed DV and k3 data at the p < 0.0 1 sig nificance level, respectively. Thus, it is unlikely that undersampling or variability in our measures masked detection of changes as large as those pre viously suggested.
The present findings do not exclude changes of greater magnitude involving small subcortical brain regions or select sUbpopulations of muscarinic re ceptors. Several previous in vitro studies have sug gested preferential losses of subcortical M2 musca rinic receptors, particularly those associated with basal forebrain cholinergic neurons (Biegon et aI., 1988; . The antagonist ligands TRB and NMPB identify cerebral muscarinic receptors as a homoge neous population, despite current knowledge that there are detectable contributions from distinct, molecularly-defined receptor subtypes designated m]-m4 in most forebrain regions (Levey et aI., 199 1; . At the present time, radioligands that ade quately differentiate these subtypes are limited (Frey and Howland, 1992) ; those with partial selec tivity do not readily enter the brain and are not amenable to in vivo applications. Thus, potential subtype-specific changes in small regions with low total receptor density cannot be directly investi gated with current PET techniques.
We conclude that there is evidence for alteration in the regional pattern of muscarinic cholinergic re ceptor density in the human brain during normal aging. Examination of parametric binding data, however, indicates that the underlying loss of cere bral binding sites is likely to be minor and that there may be a more substantial increase in cerebellar receptors. This suggests that clinical evidence for a decline in cerebral cortical cholinergic function in aging may not be ascribed to simple loss of recep tors and emphasizes the importance of presynaptic cholinergic assessments (Araujo et aI., 1990; Stro essner-Johnson et aI., 1992) . Future studies em ploying concomitant measures of presynaptic cholinergic terminals (Kuhl et aI., 1994) will be nec essary for complete characterization of the aging cholinergic nervous system and its hypothesized role in dementing illnesses.
